These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 9298680)

  • 1. SR-12813 lowers plasma cholesterol in beagle dogs by decreasing cholesterol biosynthesis.
    Berkhout TA; Simon HM; Jackson B; Yates J; Pearce N; Groot PH; Bentzen C; Niesor E; Kerns WD; Suckling KE
    Atherosclerosis; 1997 Sep; 133(2):203-12. PubMed ID: 9298680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel cholesterol-lowering drug SR-12813 inhibits cholesterol synthesis via an increased degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
    Berkhout TA; Simon HM; Patel DD; Bentzen C; Niesor E; Jackson B; Suckling KE
    J Biol Chem; 1996 Jun; 271(24):14376-82. PubMed ID: 8662919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
    Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
    Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.
    Reihnér E; Rudling M; Ståhlberg D; Berglund L; Ewerth S; Björkhem I; Einarsson K; Angelin B
    N Engl J Med; 1990 Jul; 323(4):224-8. PubMed ID: 2114543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RG 12561 (dalvastatin): a novel synthetic inhibitor of HMG-CoA reductase and cholesterol-lowering agent.
    Amin D; Gustafson SK; Weinacht JM; Cornell SA; Neuenschwander K; Kosmider B; Scotese AC; Regan JR; Perrone MH
    Pharmacology; 1993; 46(1):13-22. PubMed ID: 8434028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
    Pappu AS; Bacon SP; Illingworth DR
    J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of early cholesterol biosynthesis in rat liver: effects of sterols, bile acids, lovastatin, and BM 15.766 on 3-hydroxy-3-methylglutaryl coenzyme A synthase and acetoacetyl coenzyme A thiolase activities.
    Honda A; Salen G; Nguyen LB; Xu G; Tint GS; Batta AK; Shefer S
    Hepatology; 1998 Jan; 27(1):154-9. PubMed ID: 9425931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of lifibrol (K12.148) on the cholesterol metabolism of cultured cells: evidence for sterol independent stimulation of the LDL receptor pathway.
    Scharnagl H; Schliack M; Löser R; Nauck M; Gierens H; Jeck N; Wieland H; Gross W; März W
    Atherosclerosis; 2000 Nov; 153(1):69-80. PubMed ID: 11058701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lovastatin and simvastatin--inhibitors of HMG CoA reductase and cholesterol biosynthesis.
    Alberts AW
    Cardiology; 1990; 77 Suppl 4():14-21. PubMed ID: 2073667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of the last two enzymatic reactions in cholesterol biosynthesis in rats: effects of BM 15.766, cholesterol, cholic acid, lovastatin, and their combinations.
    Honda A; Shefer S; Salen G; Xu G; Batta AK; Tint GS; Honda M; Chen TC; Holick MF
    Hepatology; 1996 Aug; 24(2):435-9. PubMed ID: 8690416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase.
    Amin D; Rutledge RZ; Needle SN; Galczenski HF; Neuenschwander K; Scotese AC; Maguire MP; Bush RC; Hele DJ; Bilder GE; Perrone MH
    J Pharmacol Exp Ther; 1997 May; 281(2):746-52. PubMed ID: 9152381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naringin alters the cholesterol biosynthesis and antioxidant enzyme activities in LDL receptor-knockout mice under cholesterol fed condition.
    Kim HJ; Oh GT; Park YB; Lee MK; Seo HJ; Choi MS
    Life Sci; 2004 Feb; 74(13):1621-34. PubMed ID: 14738906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in human hepatoma cell line Hep G2. Effects of inhibitors of cholesterol synthesis on enzyme activity.
    Boogaard A; Griffioen M; Cohen LH
    Biochem J; 1987 Jan; 241(2):345-51. PubMed ID: 3036060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Azalanstat (RS-21607), a lanosterol 14 alpha-demethylase inhibitor with cholesterol-lowering activity.
    Burton PM; Swinney DC; Heller R; Dunlap B; Chiou M; Malonzo E; Haller J; Walker KA; Salari A; Murakami S
    Biochem Pharmacol; 1995 Aug; 50(4):529-44. PubMed ID: 7646560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation.
    Ness GC; Zhao Z; Lopez D
    Arch Biochem Biophys; 1996 Jan; 325(2):242-8. PubMed ID: 8561503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypocholesterolaemic and antiatherosclerotic effects of tetra-iso-propyl 2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethyl-1,1-diphosphonate (SR-9223i).
    Jackson B; Gee AN; Guyon-Gellin Y; Niesor E; Bentzen CL; Kerns WD; Suckling KE
    Arzneimittelforschung; 2000 Apr; 50(4):380-6. PubMed ID: 10800637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cinnamate supplementation enhances hepatic lipid metabolism and antioxidant defense systems in high cholesterol-fed rats.
    Lee JS; Jeon SM; Park EM; Huh TL; Kwon OS; Lee MK; Choi MS
    J Med Food; 2003; 6(3):183-91. PubMed ID: 14585184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.
    Naoumova RP; Marais AD; Mountney J; Firth JC; Rendell NB; Taylor GW; Thompson GR
    Atherosclerosis; 1996 Jan; 119(2):203-13. PubMed ID: 8808497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.
    Cohen LH; van Vliet A; Roodenburg L; Jansen LM; Griffioen M
    Biochem Pharmacol; 1993 Jun; 45(11):2203-8. PubMed ID: 8517861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.